Member Info for CauldStream7

Dallo;

Another valuable post from you about the scientific contribution Prof Sylvane Muller to IMM's principal drug asset, peptide platform P140.

It's her close involvement with IMM as inventor of P140 and Lupuzor, and her eminence in European science that first persuaded to invest in IMM in 2011. her continued close association also keeps me onboard.

Nolupus and Wigwammer:

Instead of trying to sort out your quarrel, why don't you read today's posts from Dallo. All the information you needed is contained in them.

Dallo:

Your last 3 posts which provide the background to the RNS today, are indeed highly informative and interesting. Thanks for explaining about the development of peptides in treating auto-immune diseases in general and for the P140 peptide platform in particular. They are very, very helpful for long term shareholders like me who sometimes have depended more on intuition than science for holding on through all the ups and downs of IMM.

I am now well into my eighties and I wonder sometimes if success will come to IMM before I expire!

Dallo;

Thanks for enlightening all of us on the collaboration between CNRS and IMM. It also explains why many of us invested in IMM in the first place, something that I for one tend to forget.

Nolupus.

Shame on all of us who are unfairly bashing you.

So now we can expect silence from you; as you say, it's not worth the effort.

Nolupus

You tell us - haven't you done your own research?

Nolupus.

I don't think you are in a position to lecture people on doing their own research to check on the truth of your unchecked and unresearched statements such as your latest on CNRS and IMM. You should read what is written on this subject in the Immupharma website before opining on this. In it you would have read that Immupharma has exclusive rights to commercialise the CNRS patents. In return, CNRS will receive 12% of Imm's revenue from royalties arising from this effort.

It is also mentioned that a new agreement on collaboration between CNRS and IMM is being discussed.

But you can find this for yourself before making statements on the subject, or are you too lazy?

Machin:

What a load of twaddle. Am I the only one who does not have a clue as to what/who GAOTU stands for?

During the past 10 years, the highest closing price was 190p on 03/01/2018. A long way short of 1200p. When was that dizzy height reached, Flash?

Flash:

I don't know if you can't read, but the RNS does NOT say, a significant deal OR a minimum of 3 years, it says AND which does not mean the same as OR.

Can't you also read the other contributors to this site who explain the full meaning of the conditions attached to the share options.

Are you a fool or a knave?

Flash:

I don't know if you can't read, but the RNS does NOT say, a significant deal OR a minimum of 3 years, it says AND which does not mean the same as OR.

Can't you also read the other contributors to this site who explain the full meaning of the conditions attached to the share options.

Are you a fool or a knave?

Flash. It is NOT the case that there are no conditions attached to the exercise of these share options. One of the three conditions is that a commercial of significant value to the company has been achieved. The Remuneration Committee will be the judge of that.

You either do not understand plain English or you are a blatant deceiver,

Nolupus: Thank you for clarifying that you are not nobbygnome.

Nolupus:

Is this a denial of Nolupus=nobbygnome? Your reply seems very gnomic, and very typical of your posts.

....Infant Drug Status which will accelerate the trial process. We all know that IMM is looking for a pharma to finance the CIDP and we believe the BOD when it says it expects to find a partner for the CIDP trial this year. There have been trials/investigations by IMM which have led to the approval by FDA of the P140 trial in the case of CIDP. FDA support for the new Phase 2/3 CIDP trial is not in doubt, only the finance for it.

Flash212:

You omit to say that meetings with FDA have been held and that FDA has given its agreement for a drug from the P140 platform can be used in an adaptive Phase 2/3 Trial on patients with CIDP.

The recent RNS issued by Immupharma on 6 March also states that an application has been drawn up in collaboration with Simbec-Orion which has been appointed as CRO to take charge of the CIDP adaptive trial to apply for CIDP for Infant Drug

Dallo:

And if is bought by a large pharma, what valuation are we looking at? Amolyt cost AZN $1.05 billion. Can you imagine a valuation much greater than that for the P140 platform of peptides, £5 billion perhaps?

Nolupus:

Thanks for your comment.

I know that it is the responsibility of the CRO, Simbec - Orion, to post information about the timetable and other details of the Lupuzor trial on the clinical trials website, but surely they keep IMM and Avion up to date on their progress. They should pass on this information to private investors like us at regular intervals.

Dallo:

Your last post was an important reminder of the correct situation in regard to the Phase 3 Lupuzor trial. Thanks.

Now, it would be helpful if we could be advised of the timings of the Phase 3 programme: when the patient recruitment will be completed; the likely spacing of the intermediate reports on the dosing regimes and similar information of the Phase 2/3 CIDP trial. It's also been a considerable time since we have had any hard news on BioAMB's progress towards commercialisation.

Dallo:

Well, it's beyond my comprehension, too.

You say the French are better at raising finance for their small research pharmas. But IMM has good French links - its labs are in Bordeaux, I believe, and the whole purpose of IMM is to commercialise the research by France's leading scientific organisation into peptides, etc. So why on earth does it not carry the sort of market valuation which Amolyt has?